| metastatic/advanced mGC or mGEJC | |||||||
| mGC or mGEJC - L1 - HER2 neg/PDL1 positive | mGC or mGEJC - L1 - HER2 negative | mGC or mGEJC - L1 - PDL1 positive | mGC or mGEJC - L2 - all population | mGC or mGEJC - L2 - PDL1 positive | mGC or mGEJC - M - HER2 negative | mGC or mGEJC - M - HER2 neg/PDL1 positive | |
| immune chekpoint inhibitors | |||||||
| anti-CTLA-4 | |||||||
| ipilimumab based treatment | |||||||
| ipilimumab alone | |||||||
| Ipilimumab (10 mg/kg) | CA184-162 | ||||||
| anti-PD-(L)1 | |||||||
| avelumab based treatment | |||||||
| avelumab alone | JAVELIN Gastric 300 | JAVELIN Gastric 100 | JAVELIN Gastric 100 ... | ||||
| nivolumab based treatment | |||||||
| nivolumab alone | ATTRACTION-2 ... | ||||||
| nivolumab plus SoC | CheckMate 649 ... CheckMate 649 ... | CheckMate 649 | |||||
| pembrolizumab based treatment | |||||||
| pembrolizumab alone | KEYNOTE-062 ... KEYNOTE-062 ... | KEYNOTE-061 ... | KEYNOTE-061 ... | ||||
| pembrolizumab plus SoC | KEYNOTE-062 ... KEYNOTE-062 ... | ||||||
Study type:
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
